Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
Emerging Therapies for Hemophilia: A New Era of Care and the Role of the Interdisciplinary Team.
Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.
Knee flexion contracture in haemophilia: treatment with circular external fixator.
Parents of children with haemophilia at an early age: assessment of perceived stress and family functioning.
Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
This page was last updated September 8, 2010 and is maintained by Betsy Wilson
Vanderbilt University is committed to principles of equal opportunity and affirmative action. Copyright 2014 © Vanderbilt University Medical Center.